Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives

Abstract Breast cancer (BC) is a complex disease with primary or acquired incurability characteristics in a significant part of patients. Immunotherapeutical agents represent an emerging option for breast cancer treatment, including the human epidermal growth factor 2 positive (HER2+) subtype. The i...

Full description

Bibliographic Details
Main Authors: E. Krasniqi, G. Barchiesi, L. Pizzuti, M. Mazzotta, A. Venuti, M. Maugeri-Saccà, G. Sanguineti, G. Massimiani, D. Sergi, S. Carpano, P. Marchetti, S. Tomao, T. Gamucci, R. De Maria, F. Tomao, C. Natoli, N. Tinari, G. Ciliberto, M. Barba, P. Vici
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Hematology & Oncology
Subjects:
Metastatic
Early
Breast cancer
Immunotherapy
Vaccine
HER2+
Online Access:http://link.springer.com/article/10.1186/s13045-019-0798-2

Internet

http://link.springer.com/article/10.1186/s13045-019-0798-2

Similar Items